GE HealthCare has entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer’s disease.
GE HealthCare said it intends to fund the transaction with cash on hand but did not disclose financial terms.
To complement its MR-guided AI-assisted scanning expertise with analysis and reporting in neurological disease assessment, GE HealthCare expects to integrate the icometrix icobrain platform with its MRI systems. Icobrain Aria includes FDA-cleared computer aided detection and diagnosis solution for detecting and quantifying known side effects of amyloid targeting therapies known as Amyloid Related Imaging Abnormalities (ARIA).
GE HealthCare intends to focus on expanding patient access to the Icobrain Aria solution on all vendor MRI systems through both commercial distribution and clinical integration. The Icobrain Aria solution identifies both forms of ARIA: ARIA-E and ARIA-H from MR scans and performs longitudinal analysis of ARIA occurrence over time. It provides radiologists with tools for monitoring Alzheimer’s patients receiving anti-amyloid therapies over the course of treatment, supporting both patient care and operational efficiency. Integrating this solution with GE HealthCare’s current MR systems and technologies, such as its deep learning offerings AIR x Brain, AIR Recon DL and SONIC DL 3D, is expected to enable a seamless, optimized workflow, allowing clinicians to manage the increased volume of scans without compromising the quality of care.
The Icometrix suite of solutions includes tools that assist radiologists and neurologists with comparing and quantifying brain MR scans over time for disorders ranging from multiple sclerosis, dementia, epilepsy, stroke and traumatic brain injury, among others. This product suite also features a strong pipeline of clinical decision support applications in development to improve neurological care in the future.
Founded in 2011, and based in Leuven, Belgium, Icometrix provides AI-powered brain imaging analysis through its Icobrain platform, offering clinicians valuable insights into neurological disorders. Icobrain extracts key data from brain MRI scans, facilitating more accurate diagnoses and personalized treatment plans across hospitals globally. Furthermore, icometrix collaborates with pharmaceutical companies to support strategic drug development, clinical trials, real-world evidence, and market access needs.
